Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1309 | 1052 | 1511 | 1721 | 3468 | 4232 |
Fund Return | 30.9% | 5.19% | 51.11% | 19.84% | 28.23% | 15.52% |
Place in category | 84 | 70 | 78 | 41 | 35 | 10 |
% in Category | 99 | 63 | 99 | 50 | 61 | 44 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Small Cap Fund Dir Bon | 622.6B | 28.41 | 30.99 | 23.96 | ||
Reliance Small Cap Fund Dir Gr | 622.6B | 27.71 | 32.10 | 24.28 | ||
Reliance Small Cap Fund Dir Div | 622.6B | 28.41 | 30.99 | 23.96 | ||
Reliance Small Cap Fund Bonus | 622.6B | 27.57 | 29.87 | 22.79 | ||
Reliance Small Cap Fund Dividend | 622.6B | 26.66 | 31.00 | 23.10 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Reliance Pharma Dividend Payout | 86.89B | 29.93 | 21.25 | 16.57 | ||
Reliance Pharma Fund - Growth | 86.89B | 30.90 | 19.84 | 15.52 | ||
Reliance Pharma Direct Bonus | 86.89B | 31.89 | 20.92 | 16.54 | ||
Reliance Pharma Direct Growth | 86.89B | 31.89 | 20.92 | 16.54 | ||
Reliance Pharma Dir Div Payout | 86.89B | 31.34 | 22.08 | 17.31 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Sun Pharma | INE044A01036 | 13.95 | 1,734.25 | -0.87% | |
Divi's Labs | INE361B01024 | 9.16 | 5,951.80 | -0.79% | |
Lupin | INE326A01037 | 8.06 | 1,998.40 | -0.40% | |
Cipla | INE059A01026 | 5.54 | 1,492.75 | +0.11% | |
Apollo Hospitals | INE437A01024 | 5.24 | 6,841.10 | -2.03% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Strong Buy |
Technical Indicators | Strong Sell | Strong Sell | BUY |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review